SPONSORED CONTENT
While federal laws and regulations set the foundation for 340B compliance, state-level laws introduce an additional layer of complexity. Covered entities (CEs) must be vigilant in understanding how these state laws can impact their operations to avoid potential compliance pitfalls. We have outlined a few
…
SPONSORED CONTENT
As the 340B program continues to grow in complexity, given the drug manufacturer restrictions, it is more important than ever for covered entities to have a firm grasp and understanding of the fees charged by their Third Party Adminisrators (TPAs) for their contract pharmacies. Whether it is
…SPONSORED CONTENT
Artificial Intelligence (AI) is making significant strides in healthcare, and its potential impact on the 340B Drug Pricing Program is becoming increasingly evident.
AI offers
…
SPONSORED CONTENT
In the complex landscape of healthcare, compliance with the Health Resources and Services Administration’s (HRSA) 340B program is paramount for covered entities. As organizations strive to optimize their participation in the program, one critical aspect is preparing for HRSA audits. To shed light on this crucial process, we
…
SPONSORED CONTENT
TIP: Enhance your 340B program efficiency through collaborative review and impact analysis.
Asking your TPA
SPONSORED CONTENT
TIP: To avoid unnecessary audit findings, it is critically important to review OPAIS data regularly.
HRSA audit
SPONSORED CONTENT
Note: The Advanced 340B Operations Certificate Program is a separate Apexus offering that is not a part of the 340B Prime Vendor Program or otherwise associated with the Prime Vendor Agreement between HRSA and Apexus.
The 340B drug pricing
…
SPONSORED CONTENT
On April 19, 2024—fourteen years after the Congressional deadline—the Health Resources and Services Administration published its final rule for the 340B Administrative Dispute Resolution process. The rule goes into effect today, June 18. Although HRSA restarted its stalled ADR rulemaking
…*Sign up for news summaries and alerts from 340B Report
